WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced Morphic COO and CFO Marc Schegerin, M.D. will participate in panel discussion titled “Novel Approaches Tackling Autoimmune Conditions” at the BMO Biopharma Spotlight Series on Inflammation & Immunology on Wednesday April 6th 2022.
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.